prikaz prve stranice dokumenta Terapija muptiple skleroze - od konvencionalnih lijekova i monoklonskih protutijela do kanabinoida
  Download
PDF 715.58 KB
Professional paper - Professional paper
Terapija muptiple skleroze - od konvencionalnih lijekova i monoklonskih protutijela do kanabinoida
Farmaceutski glasnik, 73 (2017), 3; 177-190. urn:nbn:hr:163:783947
Rajić Džolić, Zrinka; Šipicki, Sara; Perković, Ivana

Institutional repository: Repository of Faculty of Pharmacy and Biochemistry University of Zagreb

Cite this document

Rajić Džolić, Z., Šipicki, S. & Perković, I. (2017). Terapija muptiple skleroze - od konvencionalnih lijekova i monoklonskih protutijela do kanabinoida. Farmaceutski glasnik, 73. (3), 177-190. Retrieved from https://urn.nsk.hr/urn:nbn:hr:163:783947

Rajić Džolić, Zrinka, et al. "Terapija muptiple skleroze - od konvencionalnih lijekova i monoklonskih protutijela do kanabinoida." Farmaceutski glasnik, vol. 73, no. 3, 2017, pp. 177-190. https://urn.nsk.hr/urn:nbn:hr:163:783947

Rajić Džolić, Zrinka, Sara Šipicki and Ivana Perković. "Terapija muptiple skleroze - od konvencionalnih lijekova i monoklonskih protutijela do kanabinoida." Farmaceutski glasnik 73, no. 3 (2017): 177-190. https://urn.nsk.hr/urn:nbn:hr:163:783947

Rajić Džolić, Z., Šipicki, S. and Perković, I. (2017) 'Terapija muptiple skleroze - od konvencionalnih lijekova i monoklonskih protutijela do kanabinoida', Farmaceutski glasnik, 73(3), pp. 177-190. Available at: https://urn.nsk.hr/urn:nbn:hr:163:783947 (Accessed 25 November 2024)

Rajić Džolić Z, Šipicki S, Perković I. Terapija muptiple skleroze - od konvencionalnih lijekova i monoklonskih protutijela do kanabinoida. Farmaceutski glasnik [Internet]. 2017 [cited 2024 November 25];73(3):177-190. Available at: https://urn.nsk.hr/urn:nbn:hr:163:783947

Z. Rajić Džolić, S. Šipicki and I. Perković, "Terapija muptiple skleroze - od konvencionalnih lijekova i monoklonskih protutijela do kanabinoida", Farmaceutski glasnik, vol. 73, no. 3, pp. 177-190, 2017. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:163:783947. [Accessed: 25 November 2024]

Metadata
Title (croatian)Terapija muptiple skleroze - od konvencionalnih lijekova i monoklonskih protutijela do kanabinoida
AuthorZrinka Rajić Džolić
AuthorSara Šipicki
AuthorIvana Perković
Author's institutionUniversity of Zagreb
Faculty of Pharmacy and Biochemistry
(Department of medicinal chemistry)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Pharmacy
Pharmacy
Abstract (croatian)
Multiple sclerosis is an autoimmune neurodegenerative disease, with inflammation and demyelination in the central nervous system, which results in different neurological symptoms. TI1e disease is usually diagnosed as a relapsing-remittent multiple sclerosis (85 %), which is characterized by acute attacks followed by recovery. Here we describe drugs used in the therapy/management of multiple sclerosis. In the acute phase new symptoms appear or the current neurological status worsens. The standard therapy consists of high doses of methylprednizolone, which is efficacious and usually leads to a quick recovery. Disease-modifying drugs are used to reduce the frequency of relapses and to slow the progression of disability. The classical first line drugs are interferon-P and glatiramer acetate. Other drugs include fingolimod, teriflunomid, dimethylfumarate, mitoxantron, natalizumab, alemtuzumab and daclizumab. Immunosupressive agents are also used in the therapy. The third class of drugs are used to alleviate the symptoms of the disease. Here we describe the benefitial effects of cannabinoids in more detail.
Keywords (croatian)
Languagecroatian
Publication typeProfessional paper - Professional paper
Publication statusPublished
Peer reviewPeer review - domestic
Publication versionPublished version
Journal titleFarmaceutski glasnik
Numberingvol. 73, no. 3, pp. 177-190
p-ISSN0014-8202
URN:NBNurn:nbn:hr:163:783947
Publication2017
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2020-06-17 08:43:35